Therapeutical modulation of plasmacytoid dendritic cells in experimental arthritis.

Date publication

août 2017

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAHRAM Siamak , Dr CHAN Susan , Dr KASTNER Philippe , Dr KIRSTETTER Peggy , Dr MUELLER Christopher , Dr FLACHER Vincent

Tous les auteurs :
Nehmar R, Alsaleh G, Voisin B, Flacher V, Mariotte A, Saferding V, Puchner A, Niederreiter B, Vandamme T, Schabbauer G, Kastner P, Chan S, Kirstetter P, Holcmann M, Mueller C, Sibilia J, Bahram S, Blüml S, Georgel P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28777892

Résumé

The role of plasmacytoid dendritic cells (pDCs) and type I Interferons in rheumatoid arthritis (RA) remains controversial. To explore their contribution to RA pathogenesis, we induced experimental arthritis in various animal models of pDC depletion. We also monitored the effect of localized pDC recruitment and activation on joint inflammation and bone damage.

Mots clés

Adjuvants, Immunologic, pharmacology, Aminoquinolines, pharmacology, Animals, Arthritis, Experimental, genetics, Arthritis, Rheumatoid, genetics, Cytokines, drug effects, Dendritic Cells, drug effects, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Gene Expression Profiling, Humans, Ikaros Transcription Factor, genetics, Imiquimod, Interferon Type I, drug effects, Membrane Glycoproteins, genetics, Mice, Mice, Knockout, Mice, Transgenic, Reverse Transcriptase Polymerase Chain Reaction, Toll-Like Receptor 7, genetics, Tumor Necrosis Factor-alpha, genetics